Most Read Articles
01 Oct 2013

Heart disease is still New Zealand’s biggest killer, with one Kiwi dying from coronary heart disease every 90 minutes. Pharmacy Today New Zealand looks at how pharmacists can help

Pearl Toh, 11 Oct 2017
Clinical practice is an art guided by good science, and clinical practice guideline (CPG) is meant to guide in integrating the art and science of clinical practice for the long-term benefits of patients, said Dr Abdul Rashid Abdul Rahman, a consultant cardiovascular physician at An-Nur Specialist Hospital in Bangi, Malaysia, during the 13th Asian-Pacific Congress of Hypertension (APCH) held in Singapore.
08 Oct 2017
Treatment with vismodegib does not appear to increase the risk of subsequent squamous cell carcinoma (SCC) in comparison with standard surgical treatment of basal cell carcinoma (BCC), a recent study suggests.
01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute. 

Entecavir slightly better than lamivudine for patients with HBV-related AE, ACLF

08 Jul 2017

Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.

Researchers performed a comprehensive literature search of studies on therapy involving entecavir or lamivudine for chronic HBV-related acute exacerbation with or without ACLF published before December 2015.

Short- (within 4 months) and long-term (beyond 4 months) mortality were the main outcomes. The secondary outcomes were virological and biochemical responses, ACLF recurrence, and safety.

Three prospective and eight retrospective cohort studies met the inclusion criteria, involving a total of 1,491 patients. Overall, short- (risk ratio [RR], 0.99; 95 percent CI, 0.78 to 1.27) and long-term mortality rates (RR, 0.82; 0.45 to 1.52) were similar among all patients who received entecavir or lamivudine.

On the other hand, long-term outcome was more favourable in patients with ACLF who received entecavir vs lamivudine (RR, 0.60; 0.45 to 0.80). In addition, entecavir yielded more efficient virological and biochemical responses than did lamivudine with respect to the HBV DNA undetectable rate (RR, 1.34; 1.09 to 1.63), HBV DNA reduction rate (weighted mean difference, ‒0.41; ‒0.69 to ‒0.13) and serum alanine aminotransferase normalization rate (RR, 1.13; 1.05 to 1.21).

Additional larger, long-term randomized controlled trials are warranted to confirm these findings, according to researchers.

Oral nucleos(t)ide analogues are commonly given in patients with chronic HBV-related acute exacerbation and ACLF, researchers said. This study provided evidence to the safety and efficacy of entecavir and lamivudine to such patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Oct 2013

Heart disease is still New Zealand’s biggest killer, with one Kiwi dying from coronary heart disease every 90 minutes. Pharmacy Today New Zealand looks at how pharmacists can help

Pearl Toh, 11 Oct 2017
Clinical practice is an art guided by good science, and clinical practice guideline (CPG) is meant to guide in integrating the art and science of clinical practice for the long-term benefits of patients, said Dr Abdul Rashid Abdul Rahman, a consultant cardiovascular physician at An-Nur Specialist Hospital in Bangi, Malaysia, during the 13th Asian-Pacific Congress of Hypertension (APCH) held in Singapore.
08 Oct 2017
Treatment with vismodegib does not appear to increase the risk of subsequent squamous cell carcinoma (SCC) in comparison with standard surgical treatment of basal cell carcinoma (BCC), a recent study suggests.
01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute.